Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 8
Submit an article Journal homepage
67
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Dissecting the Molecular Mechanism of Chronic Myelogenous Leukemia Using Murine Models

Ruibao Ren Rosenstiel Basic Medical Sciences Research Center, Department of Biology, MS029, Brandeis University, 415 South Street, Waltham, MA 02454-9110, USA
Pages 1549-1561 | Published online: 01 Jul 2009

  • Faderl. S. Talpaz. M., Estroy. Z., O'Brien. S., Kurzrock. R. and Kantarjian. H.M. (1999) "The biology of chronic myeloid leukemia". N. Engt. J. Med. 341, 164-172.
  • Kurzrock. R., Gutterman. J. and Talpaz. M. (1988) "The molecular genetics of Philadelphia chromosome-positive leukemias". N. Enitl. J. Med. 319, 990-998.
  • Melo. J.V. (1997) "BCR-ABL gene variants". Baillieres Clin. Haematol. 10, 203-222.
  • Tefferi. A. (2001) "Chronic myeloid disorders: Classification and treatment overview". Semin. Hematol. 38, 1 -4.
  • Harris. NL. Jaffe. E.S., Diebold. J., Randrin. C., Muller-Hermelink, H.K., Varcliman. J. Lisler. T.A. and Bloomlield. C.D. (1999) "The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting. Airlie House. Virginia. November. IW. Ann. Oncol. 10, 1419-1432.
  • Deininger. M.W, Goldman. J.M. and Melo. J.V. (2000) "The molecular biology of chronic myeloid leukemia". Blood 96, 3343-3356.
  • Sawyers. CL. (1999) "Chronic mycloid leukemia". N. Engl. J. Med. 340, 1330-1340.
  • Sawyers. C.L. (2001) "Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors". Semin. Hematol. 38, 15-21.
  • Raitano. A.B., Whang. Y.E. and Sawyers, C.L. (1997) "Signal transduction by wild-type and leukemogenic AbI proteins". Biochim. Biophys. Acta 1333, F201 -F2I6.
  • Rosenberg. N. and Witte. O.N. (1988) "The viral and cellular forms of the abelson (abl) oncogene". Advances in Virus Research (Academic Press. New York) Vol. 35. pp. 39-81.
  • Jackson, P. and Baltimore. D. (1989) "N-terminal mutations activate the leukemogenic potential of the myrisloylaled form of c-abl". EMBO J. 8. 449-456.
  • Fratz, W.M., Berger, P. and Wang, J. Y.J. (1989) "Deletion of an Nterminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential". EMBO J 8, 137-147.
  • Zou, X. and Calame. K. (1999) "Signaling pathways activated by oncogenic forms of Abl tyrosine kinase". J Biol. Chent 274. 18141-18144.
  • Lugo, T.G., Pendergast. A.-M., Muller. A.J. and Witte. O.N. (1990) "Tyrosine kinase activity and transformation potency of ber-abl oncogene products". Science 247, 1079-1082.
  • Druker. B J., Tamura. S., Buchdunper. E., Ohno. S., Segal. G.M., Fanning. S., Zimmermann. J. and Lydon. N.B. (1996) "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BerAbl positive cells". Nat. Med. 2, 561-566.
  • Zhang, X. and Ren. R. (1998) "Ber-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrnphage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia". Blood 92. 3829-3840.
  • Buchdunger. E., Zimmermann. J., Mett, H., Meyer. T., Muller. M., Druker. B.J. and Lydon. N.B. (1996) "Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative". Cancer Res. 56, 100-104.
  • Heinrich. M.C., Griftith. D.J., Druker. B.J., Wait, C.L., Ott. K.A. and Zigler. A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STI 571. a selective tyrosine kinase inhibitor". Blood 96, 925-932.
  • Druker. B.J., Sawyers. C.L., Capdeville, R., Ford. J.M., Baccarani. M. and Goldman. J.M. (2001) "Chronic myelogenous leukemia". Hematology (Am. Soc. Hematol. Educ. Program.). 87- 112.
  • Gorre. M.E., Mohammed, M., Ellwood. K., Hsu. N., Paquette. R., Rao. P.N. and Sawyers. C.L. (2001) "Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification". Science 293, 876-880.
  • Sawyers. C.L. (1997) "Signal transduction pathways involved in BCR-ABL transformation". Buillieres Clin. Haemalot. 10. 223-231.
  • Verfaillie. C.M., Hurley. R., Lundell. B.I., Zhao. C. and Bhatia. R. (1997) "Integrin-mediated regulation of hematopoiests: Do BCR/ABL-induccd defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors'.'", Acta Haematol. 97, 40-52.
  • Ghaffari. S., Daley, G.Q. and Lodish, H.F. (1999) "Growth factor independence and BCR/ABL transformation: promise and pitfalls of marine model systems and assays". Leukemia 13, 1200- 1206.
  • Van Etten, R.A. (2001) "Retroviral transduction models of ph(+) leukemia: advantages and limitations for modeling human hematological malignancies in mice", Blood Cells Mol. Dis. 27. 201-205.
  • Serrano. M., Lin. A.W., McCurrach. M.E., Beach. D. and Lowe, S.W. (1997) "Oncogenic rus provokes premature cell senescence associated with accumulation of p53 and p161NK4a". Cell 88, 593-602.
  • Hahn. W.C., Counter. C.M., Lundberg. A.S., Beijersbergen. R.L., Brooks. M.W. and Weinberg. R.A. (1999) "Creation of human tumour cells with defined genetic elements". Nature 400. 464-468.
  • Wang. J.C., Lapidot. T., Cashman. J.D., Doedens. M., Addy. L., Sutherland, D.R., Nayar. R., Laraya. P., Minden, M., Keating. A., Eaves. A.C., Eaves. C.J. and Dick. J.E. (1998) "High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic mycloid leukemia in chronic phase". Blood 91, 2406-2414.
  • [281 Lewis. I.D., McDiarmid. L. A., Samels. L.M., To. L.B. and Hughes. T.P. (1998) "Establishment of a reproducible model of chronicphase chronic myeloid leukemia in NOD/SCID mice using bloodderived mononuclear or CD34 + cells". Blood 91, 630-640.
  • Zhao. R.C., Jianjj, Y. and Vcrfaillie. C.M. (2001) "A model of human p210(ber/ABL)-mediated chronic inyelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL- containing retroviral vector". Bland 97, 2406-2412.
  • Wong. S. and Witte. O.N. (2001) "Modeling Philadelphia chromosome positive leukemias". Oncogene 20, 5644-5659.
  • Heisterkamp. N., Jenster. G., Kioussis. D., Pattengale. P.K. and Grolfen, J. (1991) "Human ber-abl gene has a lethal effect on emhryogcncsis". Tram. Rex. 1, 45-53.
  • Heisterkamp. N., Jenstcr. G., ten Hoeve, J., Zovich. D., Pattengale, P.K. and Groffen. J. (1990) "Acute leukemia in ber/abl transgenic mice". Nature 344, 251-253.
  • Voncken. J.W., Griffiths, S., Greaves. M.K. Pallengale. P.K., Heisterkamp. N. and Groffen. J. (1992) "Restricted oncogenicity of BCR/ABL p190 it) transgenic mice". Cancer Res. 52. 4534-4539.
  • Voncken, J.W., Kaartinen. V., Panengale. P.K., Genneraad. W.T., Groffen. J. and Heisierkamp. N. (1995) "BCR/ABL P210 and Pl90 cause distinct leukemia in transgenic mice". Blood 86. 4603-4611.
  • Honda. H., Fujii. T., Takatoku. M., Mano, H., Witte. O.N., Yazaki, Y. and Hirai. H. (1995) "Expression of p21 Ober-abl by metallothionein promoter induced T-cell leukemia in transgenic mice". Blood 85, 2853-2861.
  • Huettner. C.S., Zhang, P., Van Etten. R.A. and Tenen. D.G. (2000) "Reveribility of acute B-cell leukemia induced by BCR-ABLI". Nat. Genet. 24, 57-60.
  • Castellanos. A., Pintado. B., Weruaga. E., Arevalo. R., Lopez. A., Orfao. A. and Sanchez-Garcia. I. (1997) "A BCR-ABL (p190) fusion gene made by homologous recomhinalion causes B-cell acute lymphoblastic leukcmias in chimeric mice with independence of the endogenous her product". Blood 90, 2168-2174.
  • Honda. H., Oda. H., Suzuki. T., Takahashi.T., Witte. O.N., Ozawa. K., Ishikawa. T., Yazaki. Y. and Hirai. H. (1998) "Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p21Ober/abl: a novel transgeoic model for human Phi-Positive leukemias". Blood 91, 2067-2075.
  • Rajewsky. K., Gu. H., Kuhn. R., Beiz. U.A., Muller, W., Roes. J. and Schwenk. F. (1996) "Conditional gene targeting". J. Clin. Invexl. 98, 600-603.
  • Daky. G.Q., Van Etten, R.A. and Baltimore. D. (1990) "Induction of chronic myelogenous leukemia in mice by the P210ber/abl gene of the Philadelphia chromosome". Science 247, 824-830.
  • Elcfanty. A.G., Hariharan. I.K. and Cory. S. (1990) "Ber-abl. the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice". Embo J. 9, 1069-1078.
  • Kelliher. M.A., McLaughlin. J., Witte, O.N. and Rosenberg. N. (1990) "Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL". Proc. Natl Acad. Sci. USA 87, 6649-6653, published ettatum appears in Proc. Nail Acad. Sci. USA Nov;87(22):9072.
  • Gishizky. M.L., Johnson-White. J. and Witte, O.N. (1993) "Efficient transplantation of Ber Abl-induced chronic myelogennus leukemia-like syndrome in mice". Proc. Natl Acad. Sci. USA 90, 3755-3759.
  • Pear. W.S., Miller. J.P., Xu. L., Pui. J.C., Soffer. B., Quackenbush, R.C., Pendergasl, A.M., Bronson. R., Aster. J.C., Scott. M.L. and Baltimore. D. (1998) "Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 ber/abl-transduced bone marrow". Blood 92. 3780-3792.
  • Li, S., Ilaria, R.L., Million, R.P., Daley. G.Q. and Van Etten. R.A. (1999) "The P190. P210. and P230 Forms of the BCR/ABL oncogene induce a similar chrome myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity". J. Exp. Med. 189, 1399-1412.
  • Hawley. R.G. (1994) "High-tiler retroviral vectors for efficient transduction of functional genes into murine hemalopoieiic stem cells". Ann. N. Y. Acad. Sci. 716. 327-330.
  • Elefanly. A.C. and Cory, S. (1992) "Hematologic disease induced in BALB/c mice by a ber abl relrovinis is influenced by the infection condilious". Mol. Cell Biol. 12, 1755-1763.
  • McWhirter. J.R. Gaalasso. D.I., and Wang. J.Y.J (1993) "A coiled-coil oligomerization domain of Ber is essential for the transforming function of Ber-Abl oncoproteins". Mol. Cell Biol. 13, 7587-7595.
  • Zhang. X., Suhrahmanyam. R., Wong. R., Gross. AW. and Ren. R. (2001) 'The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliterative disease in mice by Ber-Abl". Mol. Cell Biol. 21, 840-853.
  • Pluk. H., Dorey. K. and Superti-Furga. G. (2002) "Autoinhibition of c-Ahl". Cell 108, 247-259.
  • Gross. A.W., Zhang. X. and Ren. R. (1999) "Ber-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy". Mol. Cell Biol. 19, 6918-6928.
  • Gross. A.W. and Ren, R. (2000) "Ber-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells in vivo". Oncogene 19, 6286-6296.
  • Pawson, T. (1995) "Protein modules and signalling networks". Nature 373, 573-580.
  • Afar. D.E.H., Goga. A. McLaugldin. J., Witte. O.N. and Sawyers. C.L. (1994) "Differential complementation of Ber-Abl point mutants with c-Mye". Science 264, 424-426.
  • Goga. A., McLughlin. J., Afar. D.E. Saffran. D.C. and Witte. ON (1995) "Alternative signals to RAS for hematopoietic transformation by the BCR-ABL. oncogene". Cell 82. 981-988.
  • Cortez. D., Kadlec. L. and Pendergast. A.M. (1995) "Structural and signaling requirements for Ber-Abl-medieted transformation and inhibition of apoplosis". Mol. Cell Biol. 15, 5531-5541.
  • Oda. T., Tamura. S., Matsuguchi. T., Griffin. J.D. and J. D.B. (1995) "The SH2 domain of bl is not required for factorindependent growth induced by Ber-Abl in a murine myeloid cell line", Leukemia 9, 295-301.
  • Haria. Jr., R.L. and Van Etten, R.A. (1995) "The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells", Blood M. 3897-3904.
  • Zhang. X., Wong. R., Hao. SX., Pear. W.S. and Ren. R. (2001) "The SH2 domain of ber-Abl is not required to induce a murine mycloproliferative disease: however. SH2 signaling influences disease latency and phenotype". Blood 97, 277-287.
  • Roumiantsev. S., de Aos. I.E., Varticovski. L., Ilaria. R.L. and Van Etten. R.A. (2001) "The src homology 2 domain of Ber/'Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase", Blood 97, 4-13.
  • Li. S., Ilaria, Jr. R.L., Million, R.P., Daley. G.Q. and Van Etten. R.A. (1999) "The P190. P210. and P230 forms of the BCR/ABL oncogeoe induce a similar chronic mycloid leukemia-like syndrome in mice hut have different lymphoid leukemogenic activity". J. Exp. Med. 189, 1399-1412.
  • Hao. S.X. and Ren. R. (2000) "Expression of ICSBP is downregulated in Ber-Abl-induced murine CML-like disease, and forced coexpression of ICSBP inhibits the Ber-Abl-induced myeloproliferative disorder". Mol. Cell Biol. 20, 1149-1161.
  • Sexl. V., Piekorz. R., Moriggl. R., Rohrer. J., Brown. M.P., Bunting. K.D., Rothammer. K., Roussel, M.F. and Ihlc. J.N. (2000) "Stat5a/b contribute to inlerleukin 7-induced B-cell precursor expansion, bur ahl- and ber/abl-induced transformation are independent of stat5". Blool 96, 2277-2283.
  • Pendergast, A.M., Quilliam. L.A., Cripe. L.D., Bassing. C.H., Dai, Z., Li. N., Batzer, A, Rabun. K.M., Der. C.J., Schlessinger. J. and Gishizky. M.L., (1993) "BCR ABL-induced oncogenesis is inmliated hy direct interaction with the SH2 domain of the Grb 2 adaptor protein". Cell 75, 175-185.
  • Million. R.P. and Van Etten. R.A. (2000) "The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Ber/Abl tyrosine kinase". Blood 96. 664- 670.
  • Janssen, J.W., Ridge. S.A., Papadopoulos, P., Cotter. F., Ludwig. W.D., Funatsch, C., Rieder. H., Ostertag. W., Bartram. CR. and Wiedemann. L.M. (1995) "The fusion of TEL. and ABL in human acute lymphobiastic leukaemia is a rare event". Br. J. Haematol. 90, 222-224.
  • Golub, T.R., Goga. A., Barker. G.F., Afar. D.h., McLaughlin. J., Bohlander. S.K., Rowley. J.D., Witte. O.N. and Gilliland. D.G (1996) "Oligomerization of the ABI. tyrosine kinase by the Ets protein TEL. in human leukemia". Mol. Cell Biol. 16, 4107-4116.
  • Teglund, S., McKay, C., Schuetz, E., van Deursen, J.M., Slravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G. and Ihle, J.N. (1998) "Stat5a and Stat5b proteins have essential and nonessential. or redundant, roles in cytokine responses". Cell 93, 841-850.
  • Kieslinger, M., Woldrmm. I., Moriggl, R., Hofmann, J., Marine, J.C., Ihle, J.N., Beug, H. and Decker, T. (2000) "Antianoptotic activity of slat5 required during terminal stages of myeloid differentiation [In Process Citation]". Genes Dev. 14, 232-244.
  • Socolovsk, M., Fallon, A.b., Wang, S., Brugnara, C. and Lodish. H.F. (1999) "Fetal anemia and apoptosis of red cell progenitors in Stat5a-l-5b-l- mice: a direct role for Stat5 in Bcl-X(L) induction". Cell 98, 181-191.
  • Skorski, T., Bellacosa, A., Niehorowska-Skorska, M., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T.O., Wasik, M.A., Tsichlis, PN. and Calabretta, B. (1997) "Transformation, of hematopoietic cells by BCR/AKI. requires activation of a PI-3k/Akl-dependent pathway". Embo J. 16, 6151-6161.
  • Golub, T.R., Barker, G.F., Lovelt, M. and Gilliland, D.G. (1994) "Fusion of PDGF receptor beta to a novel els-like gene, tel, in chronic inyclomonocylic leukemia with 1(5:12) chromosomal translocation". Cell 77, 307-116.
  • Ross, T.S., Bernard, O.A., Berger, R. and Gillilatid, D.G (1998) "Fusion of Hunlingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDCFbewR) in chronic myelomonocytic leukemia with t(5:7)(q 33:q11.2)", Blood 91, 4419-4426.
  • Kulkarni, S., Heath. C., Parker, S., Chase, A., Iqbal, S., Pocock, C.F., Kaeda, J., Cwynarski, K., Goldman, J.M. and Cross, N.C. (2000) "Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33:q2l)". Cancer Res. 60, 3592-3598.
  • Magnusson, M.K., Meade, K.E., Brown, K.E., Arthur, D.C., Krueger, L.A., Barren, A.J. and Dunbar. C.E. (2001) "Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic inyelonionocytic leukemia". Blood 98, 2518-2525.
  • Pebusque, M.J., Chaffanet, M., Popovici, C. and Birnbaum, D. (2000) "FGFRI and MOZ. two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8pl1-12". Bull. Cancer 87, 887-894.
  • Demiroglu, A., Steer, E.,I., Heath, C., Taylor, K., Beutley, M., Allen, S.L., Koduru, P., Brody, J.P., Hawson, G., Rodwell, R., Doody, M.I.,. Carnicero, F., Reiter, A., Goldman, J.M., Melo, J.V. and Cross, N.C. (2001) "The t(8:22) in chronic myeloid leukemia fuses BCR to FGFRI: transforming activity and specific inhibition of FGFRI fusion proteins". Blood 98, 3778-3783.
  • Lucronique, V, Boureux, A., Monni, R., Dumon, S., Mauchauffe, M., Mayeux, P., Gouilleux, F., Berger, R., Gisselbrecht, S., Ghysdael, J. and Bernard, O.A. (2000) "Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells". Blood 95. 2076-2083.
  • Iijima, Y., Ito, T., Oikawa, T., Eguchi, M., Eguchi-Ishimae, M., Kamada, N., Kishi, K., Asano, S., Sakaki, Y. and Salo, Y. (2000) "A new KTV6/TEL partner gene, ARG (ABL-related gene or ABL2). identified in an AMU-M3 cell line with a t(1:12)(q25;p13) translocation". Blood 95, 2126-2131.
  • Eguchi, M., Eguchi-Ishimae,M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F. Asano, S. and Kamada, N. (1999) "Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12:15)(p13:q25|", Blood 93, 13551363.
  • Griffin, J.D. (2001) "Point mutations in the FLT3 gene in AML". Blood, 2193A-22193.
  • Longley, B.J., Reguera, M.I., and Ma, Y. (2001) "Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy", Leuk. Res. 25, 571-576.
  • Schwaller, J., Franlsve, J., Aster, J., Williams, I.R., Tomasson, M.H., Ross, T.S., Peeters, P., Van Rompaey, L., Van Etten, R.A., Haria, Jr. R., Marynen, P. and Gilliland, D.G. (1998) "Transformation of hemaiopoietic cell lines to growth-factor independence and induction of a fatal myclo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusiou genes". eMBO j. 17, 5321-5333.
  • Tomasson, M.H., Williams, I.R., Hasserjian, R., Udomsakdi, C., McGrath, S.M., Schwaller, J., Druker, B and Gilliland, D.G. (1999) "TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor". Blood 93, 1707-1714.
  • Liu, Q., Schwaller, J., Kutok, J., Cain, D., Aster, J.C., Williams, l.R. and Gilliland, D.G. (2000) "Signal transduclion and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia". Embo J. 19, 1827-1838.
  • Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. and Gilliland, D.G. (2002) "FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model". Blood 99, 310-318.
  • Tomasson, M.H., Sternberg, D.W., Williams, l.R., Carroll, M., Cain. D., Aster, J.C., Haria, Jr., R.L., Van Ellen, R.A. and Gilliland, D.G. (2000) "Fatal myeloprouferation. induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR lyrosines 579/581". J. Clin. Invest. 105, 423-432.
  • Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J.C., Williams, I.R., Lee. C.K., Gerthner, R., Kitamura, T., Framsve, J., Anastasiadou, K., Loh, ML., Levy, D.E., Ihle, J.N. and Gilliland, D.G. (2000) "Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2", Mol. Cell 6, 693-704.
  • Gomez-Lechon, MJ. (1999) "Oncostatin M: signal transduction and biological activity". Life Sci 65, 2019-2030.
  • Yoshimura, A., Ichihara, M., Kinjyo, I., Moriyama, M., Copeland. N.G., Gilbert, D.J., Jenkins, N.A., Hara, T. and Miyajima, A. (1996) "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway". Embo J. 15, 1055-1063, abs.html.
  • el-Ahmady, O., Mansour, M., Kamel, H. and Baker, A. (1997) "Granulocyte-macrophage colony stimulating factor and interleukin-6 enhanced white blood cell synthesis of leukotrienes in chronic myelogenous leukemia". Anticancer Res. 17, 3179-3182.
  • Jonuteit, T., Peschel, C., Schwab, R., van der Kuip, H., Buchdunger, E., Fischer, T., Huber, C. and Aulitzky, W.E. (1998) "Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors", Br. J. Haematol. 100, 295-303
  • Jiang, X., Lopez, A., Holyoake, T., Eaves, A. and Eaves, C. (1999) "Autocrine production and action of IL-3 and granulocyle colony-stimulating factor in chronic myeloid leukemia [In Process Citation]", Proc. Natl Acad. Sci. USA 96, 12804-12809.
  • Li. S., Gillessen, S., Tomasson, M.H., Dranoff, G., Gilliland, D.G. and Van Etten, R.A. (2001) "Interleukin 3 and granulocytemacrophagc colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL". Blood 97, 1442-1450.
  • Tomasson, M.H., Williams, I.R., Li, S., Kutok, J., Cain, D., Gitlessen, S., Dranoff, G., Van Etten, R.A. and Gilliland, D.G. (2001) "Induction of myeloproliferalive disease in mice by lyrosine kinase fusion oncogencs does not require granulocytemacrophage colony- stimulating factor or interleukin-3". Blood 97, 1435-1441.
  • Ahuja, H.G., Popplewell, L., Tcheurekdjian, L. and Slovak, M.L. (2001) "NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia", denes Chromosomes Cancer 30, 410-415.
  • Daley, G.Q., Van Ellen, R.A. and Baltimore, D. (1991) "Blast crisis in a murine model of chronic myelogenous leukemia''. Proc. Natl Acad. Sci. USA 88, 11335-11338.
  • Honda, H., Ushijima, T., Wakazono, K., Oda, H., Tanaka, Y., Aizawa, S., Ishikawa, T., Yazaki, Y. and Hirai, H. (2000) "Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis of human CML", Blood 95, 1144-1150.
  • Cuenco, O.M., Nucifora, G. and Ren, R. (2000) "Human ANILI/MDSI/EVII fusion protein induces an acute myelogenous leukemia (AML) in mice: a novel model for human AML". Proc. Natl Acad. Sci. USA 97, 1760-1765.
  • Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A.H. and Speck, N.A. (1996) "Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis". Proc. Natl Acad. Sci. USA 93, 3444-3449.
  • Ycrgeau, D.A., Hetherington, C.J., Wang, Q., Zhang, P., Sharpe. A.H., Binder, M., Mario-Padilla, M., Tenen, D.G., Speck, N.A. and Zhang, D.E. (1997) "Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AMLl-ETO fusion gene", Nat. Genet. 15, 303-306.
  • Okuda, T., van Deursen, J., Hiebert, S.W., Grosveld, G. and Downing, J.R. (1996) "AMLI, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis". Cell 84, 321-330.
  • Okuda, T., Cai, Z. Yang, S., Lenny, N., Lyu, C.,. van Deursen. J.M., Harada, H. and Downing, J.R. (1998) "Expression of a knocked-in AMLI-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors". Blood 91, 3134-3143.
  • Niki, M., Okada, H., Takano, H., Kuno, J., Tani, K., Hibino, R. Asano, S., Ho. Y, Salake, M. and Noda, T. (1997) "Hematopoiesis in the fetal liver Ls impaired by targeted mutagenesis of a gene encoding a non-DMA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor". Proc. Natl Acad. Sci. USA 94, 5697-5702.
  • Casulla, L.H., Wijmenga, C., Wang, Q., Stacy, T., Speck, N.A., Eckhaus, M., Marin-Padilla, M., Collins, F.S., Wynshaw-Boris, A. and Liu, P.P. (1996) "Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11". Cell 87, 687-696.
  • Cuenco, G.M. and Ren, R. (2001) "Cooperation of BCR-ABL and AMLI/MDSI/EVII in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia". Oncogene 20, 8236-8248.
  • Hanahan, D. and Weinberg, R.A. (2000) "The hallmarks of cancer". Cell 100, 57-70.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.